X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ALEMBIC LTD VENUS REMEDIES/
ALEMBIC LTD
 
P/E (TTM) x -862.0 125.2 - View Chart
P/BV x 0.3 4.6 5.4% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   ALEMBIC LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ALEMBIC LTD
Mar-16
VENUS REMEDIES/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs21853 412.9%   
Low Rs8229 280.2%   
Sales per share (Unadj.) Rs365.64.7 7,746.7%  
Earnings per share (Unadj.) Rs1.58.8 16.9%  
Cash flow per share (Unadj.) Rs37.99.0 421.2%  
Dividends per share (Unadj.) Rs00.15 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs382.527.7 1,379.7%  
Shares outstanding (eoy) m11.44267.03 4.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.48.7 4.7%   
Avg P/E ratio x101.04.7 2,158.1%  
P/CF ratio (eoy) x4.04.6 86.8%  
Price / Book Value ratio x0.41.5 26.5%  
Dividend payout %01.7 0.0%   
Avg Mkt Cap Rs m1,71710,962 15.7%   
No. of employees `0001.0NA-   
Total wages/salary Rs m324238 136.3%   
Avg. sales/employee Rs Th4,100.7NM-  
Avg. wages/employee Rs Th318.0NM-  
Avg. net profit/employee Rs Th16.7NM-  
INCOME DATA
Net Sales Rs m4,1831,260 331.9%  
Other income Rs m20264 7.6%   
Total revenues Rs m4,2031,524 275.8%   
Gross profit Rs m81283 980.2%  
Depreciation Rs m41761 678.8%   
Interest Rs m3800 126,600.0%   
Profit before tax Rs m35285 12.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m186 296.7%   
Profit after tax Rs m172,343 0.7%  
Gross profit margin %19.46.6 295.3%  
Effective tax rate %51.62.1 2,408.4%   
Net profit margin %0.4185.9 0.2%  
BALANCE SHEET DATA
Current assets Rs m2,7711,689 164.1%   
Current liabilities Rs m1,931486 397.2%   
Net working cap to sales %20.195.4 21.0%  
Current ratio x1.43.5 41.3%  
Inventory Days Days125217 57.6%  
Debtors Days Days5481 66.3%  
Net fixed assets Rs m5,3281,624 328.1%   
Share capital Rs m114534 21.4%   
"Free" reserves Rs m4,1775,960 70.1%   
Net worth Rs m4,3767,404 59.1%   
Long term debt Rs m1,911104 1,831.7%   
Total assets Rs m8,4288,010 105.2%  
Interest coverage x1.1950.7 0.1%   
Debt to equity ratio x0.40 3,099.0%  
Sales to assets ratio x0.50.2 315.4%   
Return on assets %4.729.3 16.1%  
Return on equity %0.431.6 1.2%  
Return on capital %6.631.3 21.1%  
Exports to sales %02.9 0.0%   
Imports to sales %20.528.9 71.1%   
Exports (fob) Rs mNA37 0.0%   
Imports (cif) Rs m858364 236.0%   
Fx inflow Rs m037 0.0%   
Fx outflow Rs m858365 235.2%   
Net fx Rs m-858-328 261.8%   
CASH FLOW
From Operations Rs m469346 135.6%  
From Investments Rs m29-48 -61.3%  
From Financial Activity Rs m-464-301 154.0%  
Net Cashflow Rs m35-3 -1,150.0%  

Share Holding

Indian Promoters % 32.9 64.0 51.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.2 90.0%  
FIIs % 0.6 9.7 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 26.1 254.4%  
Shareholders   20,121 54,701 36.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare VENUS REMEDIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Sensex Touching Record Highs, Rally in Banking Stocks and Key Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,000 on Wednesday and further inched upwards to end yesterday's trade at a level of 35,260.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 18, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - SUVEN LIFE COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS